Supplier
Port City Operating Company, LLC
Port City Operating Company, LLC was paid $121.39M by Medicaid between Jan 2018 and Dec 2024, across 330 billing codes. Its largest line is 0450, Emergency room services — 45% of everything it billed.
33Billing provider infoPORT CITY OPERATING COMPANY, LLC
STOCKTON, CA 95204
STOCKTON, CA 95204
33aNPI1528190931assigned 03/12/2007
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$121.39M
24GClaims1,873,230
24DCodes billed330
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in California
Rank by total paid#4 of 946
Median peer was paid$15K
This provider vs. median7,961×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 277,794 | $15.44M | |
| 2019 | 289,075 | $17.92M | |
| 2020 | 197,907 | $12.82M | |
| 2021 | 193,823 | $13.19M | |
| 2022 | 281,980 | $21.05M | |
| 2023 | 322,859 | $22.41M | |
| 2024incomplete | 309,792 | $18.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 45% | 213,960 | 189,153 | $54.79M |
| 80053 | Comprehensive metabolic panel | 11% | 106,388 | 96,918 | $13.70M |
| 0250 | 8.8% | 133,189 | 63,422 | $10.74M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 11,242 | 10,472 | $3.65M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.3% | 8,822 | 8,108 | $2.77M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.0% | 8,675 | 8,098 | $2.37M |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 21,054 | 20,492 | $2.16M |
| 0762 | 1.7% | 3,251 | 1,762 | $2.05M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.3% | 11,273 | 10,098 | $1.59M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 10,073 | 9,099 | $1.42M |
| 83880 | 1.0% | 12,771 | 11,761 | $1.25M | |
| 71045 | Radiologic examination, chest; single view | <1% | 35,116 | 33,331 | $970K |
318 more codes
| 0206 | <1% | 342 | $930K | |
| 87631 | <1% | 4,102 | $802K | |
| 86850 | <1% | 5,692 | $760K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 16,311 | $754K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,381 | $730K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,388 | $711K |
| Z7502 | <1% | 17,696 | $667K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 10,936 | $659K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 8,571 | $651K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,905 | $642K |
| 77386 | <1% | 1,678 | $605K | |
| 0510 | <1% | 3,594 | $550K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,404 | $537K |
| 0160 | <1% | 968 | $470K | |
| 97139 | <1% | 19,965 | $451K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 105,841 | $429K |
| 77300 | <1% | 613 | $405K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 62,327 | $315K |
| 73562 | <1% | 2,857 | $311K | |
| 73610 | <1% | 2,240 | $309K | |
| 84484 | <1% | 33,503 | $301K | |
| Z9725 | <1% | 6,798 | $292K | |
| 73030 | <1% | 2,941 | $275K | |
| 87186 | <1% | 5,753 | $259K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,058 | $246K |
| 86780 | <1% | 32,317 | $246K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,452 | $243K |
| 73630 | <1% | 2,668 | $243K | |
| 73130 | <1% | 2,016 | $237K | |
| 93458 | <1% | 202 | $234K | |
| J3490 | Unclassified drugs | <1% | 71,112 | $229K |
| 97750 | <1% | 5,195 | $225K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,547 | $216K |
| 74018 | <1% | 2,389 | $212K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 23,757 | $208K |
| 72100 | <1% | 1,584 | $208K | |
| 83605 | <1% | 16,643 | $206K | |
| 0761 | <1% | 1,155 | $201K | |
| G0299 | Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes | <1% | 724 | $198K |
| 76830 | Ultrasound, transvaginal | <1% | 4,390 | $186K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,543 | $184K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 937 | $169K |
| 73110 | <1% | 1,294 | $164K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,236 | $164K |
| 81003 | <1% | 16,113 | $150K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 23,839 | $144K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,624 | $140K |
| 77301 | <1% | 162 | $135K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,429 | $135K |
| 81001 | <1% | 45,892 | $135K | |
| 82962 | <1% | 14,107 | $133K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 22,839 | $130K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,225 | $129K |
| 77334 | <1% | 543 | $128K | |
| 93971 | <1% | 1,970 | $124K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,754 | $122K |
| 83690 | <1% | 37,936 | $120K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 316 | $119K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 870 | $114K |
| 77066 | Tomosynthesis, mammo | <1% | 1,033 | $113K |
| 76801 | <1% | 3,737 | $109K | |
| 73502 | <1% | 1,147 | $104K | |
| 77336 | <1% | 2,478 | $103K | |
| 76642 | <1% | 1,787 | $102K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,713 | $100K |
| 70486 | <1% | 771 | $99K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 164 | $94K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,421 | $93K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,714 | $91K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26,773 | $86K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,136 | $84K |
| 72040 | <1% | 566 | $83K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,210 | $82K |
| 82803 | <1% | 8,713 | $80K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,994 | $78K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,070 | $78K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 9,307 | $78K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 41 | $76K |
| 77065 | Tomosynthesis, mammo | <1% | 898 | $73K |
| 87420 | <1% | 313 | $73K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 870 | $72K |
| 84702 | <1% | 14,150 | $72K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,117 | $72K |
| 76641 | <1% | 998 | $72K | |
| 86900 | <1% | 7,283 | $69K | |
| 97802 | <1% | 467 | $68K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 783 | $67K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 212 | $65K |
| 71250 | <1% | 656 | $64K | |
| G0378 | Hospital observation service, per hour | <1% | 551 | $63K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 380 | $62K |
| 76770 | <1% | 1,135 | $62K | |
| 73080 | <1% | 652 | $62K | |
| 97799 | <1% | 2,242 | $61K | |
| 86803 | <1% | 21,297 | $60K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,671 | $59K |
| 0272 | <1% | 1,082 | $54K | |
| 59025 | Fetal non-stress test | <1% | 6,398 | $53K |
| 74183 | <1% | 227 | $52K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 537 | $49K |
| G0151 | Services performed by a qualified physical therapist in the home health or hospice setting, each 15 minutes | <1% | 175 | $48K |
| 87428 | <1% | 448 | $46K | |
| 87077 | <1% | 6,193 | $46K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,503 | $42K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,544 | $42K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,649 | $39K |
| 85730 | <1% | 11,900 | $39K | |
| 85610 | <1% | 23,137 | $39K | |
| Z7610 | <1% | 6,354 | $37K | |
| 73590 | <1% | 992 | $37K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 42,044 | $36K |
| 71101 | <1% | 185 | $35K | |
| 99199 | Unlisted special service, procedure or report | <1% | 713 | $35K |
| 83735 | <1% | 11,595 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,058 | $33K |
| J1815 | Injection, insulin, per 5 units | <1% | 2,306 | $33K |
| 77338 | <1% | 194 | $33K | |
| 76870 | <1% | 554 | $30K | |
| 81025 | <1% | 12,391 | $30K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,380 | $30K |
| 85027 | <1% | 11,498 | $30K | |
| 86308 | <1% | 268 | $29K | |
| 87040 | <1% | 6,558 | $29K | |
| 70498 | <1% | 395 | $25K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,304 | $24K |
| 0270 | <1% | 17,808 | $24K | |
| 72110 | <1% | 245 | $23K | |
| 77080 | <1% | 653 | $22K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 302 | $21K |
| 93970 | <1% | 275 | $21K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 275 | $21K |
| 70496 | <1% | 335 | $21K | |
| 74170 | <1% | 108 | $21K | |
| 85379 | <1% | 4,418 | $21K | |
| 87641 | <1% | 2,148 | $20K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,336 | $20K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,561 | $19K |
| 74178 | <1% | 85 | $19K | |
| 93325 | <1% | 189 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,481 | $17K |
| 76536 | <1% | 349 | $17K | |
| 86592 | <1% | 2,156 | $17K | |
| 82550 | <1% | 5,754 | $17K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,477 | $16K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,765 | $16K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,240 | $15K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 42 | $15K |
| 72131 | <1% | 132 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,381 | $15K |
| 85007 | <1% | 9,366 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 833 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,876 | $12K |
| 73090 | <1% | 456 | $12K | |
| J2704 | Injection, propofol, 10 mg | <1% | 454 | $12K |
| 97803 | <1% | 166 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,741 | $11K |
| 84703 | <1% | 3,461 | $11K | |
| 86901 | <1% | 7,279 | $11K | |
| 73564 | <1% | 292 | $11K | |
| 96376 | <1% | 348 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 11,065 | $9K |
| 99070 | <1% | 1,374 | $9K | |
| 86140 | <1% | 5,680 | $9K | |
| 77470 | <1% | 26 | $9K | |
| 99152 | <1% | 541 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 26 | $9K |
| 73620 | <1% | 223 | $8K | |
| 82330 | <1% | 2,685 | $7K | |
| 93798 | <1% | 282 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,069 | $7K |
| 87634 | <1% | 32 | $7K | |
| 90715 | <1% | 1,605 | $6K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 875 | $6K |
| 74019 | <1% | 75 | $6K | |
| 77412 | <1% | 137 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,176 | $6K |
| 86738 | <1% | 240 | $6K | |
| 84132 | <1% | 1,383 | $6K | |
| 84439 | <1% | 597 | $6K | |
| 74174 | <1% | 89 | $6K | |
| 87081 | <1% | 831 | $5K | |
| 93308 | <1% | 247 | $5K | |
| 93320 | <1% | 88 | $5K | |
| 97161 | <1% | 136 | $5K | |
| 84100 | <1% | 3,032 | $5K | |
| 82553 | <1% | 2,712 | $5K | |
| 83050 | <1% | 2,845 | $5K | |
| 93976 | <1% | 27 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 909 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,857 | $4K |
| 82375 | <1% | 2,762 | $4K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 55 | $4K |
| 80061 | Lipid panel | <1% | 936 | $4K |
| 87147 | <1% | 1,008 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,018 | $4K |
| 70360 | <1% | 43 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 803 | $4K |
| 84295 | <1% | 807 | $4K | |
| 83615 | <1% | 260 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 449 | $4K |
| 85652 | <1% | 2,442 | $3K | |
| 94729 | <1% | 64 | $3K | |
| 88720 | <1% | 902 | $3K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 44 | $3K |
| 73560 | <1% | 84 | $3K | |
| 94726 | <1% | 62 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,861 | $3K |
| 82947 | <1% | 476 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 338 | $3K |
| 82140 | <1% | 1,023 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 109 | $3K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 41 | $2K |
| 82009 | <1% | 1,667 | $2K | |
| 73600 | <1% | 134 | $2K | |
| 75574 | <1% | 12 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 580 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,271 | $2K |
| 99153 | Mod sedat endo service >5yrs | <1% | 286 | $2K |
| 84145 | <1% | 457 | $2K | |
| 94060 | <1% | 65 | $2K | |
| 71271 | <1% | 25 | $2K | |
| 85384 | <1% | 120 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,796 | $2K |
| 82435 | <1% | 793 | $2K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 12 | $2K |
| 0710 | <1% | 206 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,725 | $2K |
| 0370 | <1% | 326 | $1K | |
| 71020 | <1% | 77 | $1K | |
| 73120 | <1% | 59 | $1K | |
| 0352 | <1% | 119 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,512 | $1K |
| 76937 | <1% | 70 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,435 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 121 | $1K |
| 82150 | <1% | 1,417 | $1K | |
| 95819 | <1% | 26 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 565 | $1K |
| 83930 | <1% | 280 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 15 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 129 | $1K |
| 93312 | <1% | 12 | $1K | |
| 86593 | <1% | 875 | $982.29 | |
| 10060 | <1% | 41 | $966.32 | |
| 92522 | <1% | 13 | $947.40 | |
| 85018 | <1% | 962 | $932.49 | |
| 0301 | <1% | 595 | $864.15 | |
| 86923 | <1% | 31 | $792.51 | |
| 80051 | <1% | 188 | $790.47 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 559 | $772.48 |
| 84550 | <1% | 272 | $729.63 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 515 | $684.81 |
| 82565 | <1% | 244 | $655.76 | |
| 87430 | <1% | 484 | $611.58 | |
| 70491 | <1% | 24 | $592.17 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 385 | $584.95 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 181 | $575.00 |
| 93880 | <1% | 13 | $554.36 | |
| 82010 | <1% | 225 | $550.70 | |
| 87070 | <1% | 143 | $548.39 | |
| 73060 | <1% | 124 | $547.68 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 159 | $544.72 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 37 | $504.24 |
| 84520 | <1% | 215 | $481.21 | |
| 84436 | <1% | 12 | $475.00 | |
| 73140 | <1% | 52 | $450.08 | |
| 0305 | <1% | 540 | $282.35 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 12 | $278.85 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 154 | $273.54 |
| 80164 | <1% | 68 | $257.82 | |
| 85347 | <1% | 52 | $249.68 | |
| 71010 | <1% | 14 | $248.18 | |
| 0324 | <1% | 373 | $244.09 | |
| 73552 | <1% | 96 | $221.10 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 22 | $217.51 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 13 | $172.14 |
| 87529 | <1% | 42 | $149.12 | |
| 82570 | <1% | 109 | $134.37 | |
| 84156 | <1% | 108 | $125.08 | |
| 0300 | <1% | 550 | $122.62 | |
| 96367 | <1% | 39 | $117.11 | |
| 73100 | <1% | 15 | $106.90 | |
| 87210 | <1% | 61 | $105.35 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 51 | $88.11 |
| 0306 | <1% | 477 | $87.54 | |
| 82247 | <1% | 12 | $85.20 | |
| 73070 | <1% | 13 | $71.73 | |
| 92610 | <1% | 12 | $61.87 | |
| 36600 | <1% | 12 | $57.14 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 12 | $51.97 |
| 0730 | <1% | 385 | $51.80 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 20 | $47.46 |
| 0307 | <1% | 272 | $45.87 | |
| 72170 | <1% | 36 | $44.95 | |
| 82438 | <1% | 41 | $37.68 | |
| Q3014 | Telehealth originating site facility fee | <1% | 14 | $35.34 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 12 | $31.41 |
| 97116 | <1% | 23 | $29.99 | |
| 0258 | <1% | 536 | $26.31 | |
| 96368 | <1% | 12 | $18.79 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 26 | $17.28 |
| 82272 | <1% | 26 | $9.72 | |
| 87205 | <1% | 12 | $8.66 | |
| 0636 | <1% | 142 | $7.59 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 37 | $7.11 |
| 82248 | <1% | 12 | $1.20 | |
| A9270 | Non-covered item or service | <1% | 1,459 | $0.80 |
| 0424 | 0% | 28 | $0.00 | |
| 0483 | 0% | 42 | $0.00 | |
| 0402 | 0% | 13 | $0.00 | |
| 0361 | 0% | 13 | $0.00 | |
| 0412 | 0% | 12 | $0.00 | |
| 0302 | 0% | 13 | $0.00 | |
| A9150 | Non-prescription drugs | 0% | 542 | $0.00 |
| 0420 | 0% | 179 | $0.00 | |
| 0250R | 0% | 12 | $0.00 | |
| 84479 | 0% | 12 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORISETTE, DANIEL (CHIEF FINANCIAL OFFICER)
Parent organizationPORT CITY OPERATING COMPANY, LLC
| Provider | Location | Paid |
|---|---|---|
| Port City Operating Company, LLC | Stockton, CA | $6.24M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.